- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04839588
Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study (TCIFCU)
Home-based Virtual Reality System for the Treatment of Chemotherapy-related Cognitive Impairments
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations.
Perform usability study on 2 elderly healthy volunteers and 2 breast cancer survivors with lasting cognitive impairments following chemotherapy, so to improve the product design. The usability evaluation will be done at NJ Bioscience Center (North Brunswick, NJ).
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
The study will generate data on ease of use of a system for subjects with stage II or stage III breast cancer survivors with lasting cognitive impairments subsequent to their first chemotherapy regimen. The usability component will uncover technical issues in its usability, as well as its rating on perceived usefulness. Data will also be collected on the ease of remote monitoring of the subjects by clinicians.
This portion of the study is intended to provide information pertaining to the usability of the experimental system for remote integrative (cognitive and motor) therapy of breast cancer survivors (Stage II or III) with lasting chemotherapy related cognitive impairment (CRCI) subsequent to first chemotherapy regimen, living in the community.
Specific aims are:
- testing of a added biosensors, new technology acceptance and ease of use at home by these individuals;
- a caregiver console and enhanced automatic session report that will allow remote monitoring of patient exercising and offline data processing and review.
Participants will each perform 4 usability evaluation sessions. At the end of each session participants will fill a custom evaluation form, using 5-point Likert scale scoring. At the end of the last session participants will also fill a USE standardized usability evaluation form.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
New Jersey
-
North Brunswick, New Jersey, Vereinigte Staaten, 08902
- Bright Cloud Int'l Corp
-
North Brunswick, New Jersey, Vereinigte Staaten, 08902
- New Jersey Bioscience Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
At NJ Bioscience Center Healthy Volunteers
- Female
- Age 20 to 65;
- Good or corrected hearing;
- Good or corrected vision;
- No motor or cognitive impairments;
- English speakers;
- Those with low propensity for simulation sickness (as determined by the Simulation Sickness Questionnaire [Kennedy et al, 1993]).
- Either healthy or having had stage II or stage III breast cancer;
- Montreal Cognitive Assessment (MoCA) Score 10-25 indicating mild to moderate impairment [Chapman 2016] or 26-30 indicating normal cognition;
EXCLUSION CRITERIA
- Male;
- Female participants younger than 20 or older than 65;
- High propensity for simulation sickness (as determined by Simulation Sickness Questionnaire screening);
- Those with severe visual neglect or legally blind;
- Those with severe hearing loss or deafness;
- Those with uncontrolled hypertension (>190/100 mmHg);
- Those with severe cognitive impairment (MoCA score<10);
- Current diagnosis of moderate-severe depression (Beck Depression Inventory II score of 17-63);
- a history of psychiatric illness, defined as serious psychiatric illness such as bipolar mood disorder and schizophrenia, or requiring psychiatric hospitalization.
- a history of or current substance abuse;
- a previous head injury resulting in loss of consciousness;
- a prior diagnosis of neurological illness;
- a current or prior diagnosis of brain cancer;
- non-English speakers;
- Those unable to reliable participate in pre-study assessment due to any reason;
- Those with co-morbidities limiting arm and neck motor function (ex. lymphedema, chronic pain, severe arthritis);
- Less than 1 month post first chemotherapy regimen or starting chemotherapy during 16 weeks post screening (as chemotherapy during study participation is a confounding factor);
- Those with Stage IV (metastatic) breast cancer will be excluded;
- Those presenting with multiple cancers, such as breast and arm bone cancer, or breast and brain cancer;
- Those who are unwilling to allow a home inspection to ascertain Internet quality, determine best placement for the experimental or sham systems, for installation and removal of the systems and necessary repairs.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Usability study, healthy volunteers and those with cognitive impairments following chemotherapy
2 elderly healthy volunteers and 2 participants with lasting cognitive impairments following chemotherapy for breast cancer. All will perform evaluation of a computer-based experimental system. Participants will be
|
Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form. This usability evaluation will be conducted at the NJ Bioscience Center. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
USE questionnaire to assess the usability of a computerized system
Zeitfenster: At the end of the 4th evaluation session (about 1 month from enrollment)
|
A standardized questionnaire to assess the usefulness, satisfaction and ease of use of the experimental system [Lund, 2001] when evaluated by study participants. The form consists of 30 questions, each rated on a 7-point Likert scale (1 worst 7 best). The score range for this form is 30 (min) to 210 (max). Participants will also be able to comment in free form on aspects they liked most and least about the device. |
At the end of the 4th evaluation session (about 1 month from enrollment)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Subjective rating questionnaire of the device and therapy
Zeitfenster: At each of 4 evaluation sessions over 1 month from enrollment
|
Participants rate the usefulness, satisfaction issues, and ease of use of the experimental system and its therapeutic games, as well as ease of use of the Caregiver laptop.
The Subjective Evaluation Form consists of questions, each rated on a 5-point Likert scale (1 worst to 5 best outcome).
|
At each of 4 evaluation sessions over 1 month from enrollment
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Simulation Sickness Questionnaire for participant
Zeitfenster: Screening at consent (one time)
|
Form used at screening post-consent to determine a participant's propensity for simulation sickness [Kennedy et al.,1993].
The questionnaire asks participants to score 16 symptoms on a four point scale (0-3).
Score range is 0 (best outcome - no likelihood of experiencing simulation sickness with the device) to 48 (worst outcome - certainty that the participant will experience severe simulation sickness).
|
Screening at consent (one time)
|
|
Cyber-sickness Susceptibility Questionnaire for participant
Zeitfenster: Screening at consent (one time)
|
Form used at screening post-consent to determine a participant's propensity for simulation sickness [Freiwald et al., 2020].
The questionnaire asks participants 26 questions The first 13 questions ascertain the general heath and fitness of the subject, and have Yes/No answers The remaining 13 questions are score on a on a 5 point Likert scale, with five point Likert scales, referring to the frequency of each complaint's occurrence.
These scales range from 0 to 4 with the labels "very rarely", "rarely", "occasionally", "frequently" and "very often".
|
Screening at consent (one time)
|
|
Montreal Cognitive Assessment (MoCA) to measure level of cognitive impairment
Zeitfenster: Screening at consent (one time)
|
Used at screening post-consent to determine level of cognitive impairment [Nasreddine et al 2005] for participants.
The form has a score range from 0 (worst) to 30 (best) - no cognitive impairments.
For the participants with early Alzheimer's Disease the form will confirm the participant is in the score range of 19-25.
|
Screening at consent (one time)
|
|
Biosensor readings
Zeitfenster: At each of 4 evaluation sessions over 1 month from enrollment
|
Custom biosensors will provide additional data which will be used to gauge levels of cognitive engagement with the tasks performed during the evaluation.
|
At each of 4 evaluation sessions over 1 month from enrollment
|
|
Game difficulty level
Zeitfenster: At each of 4 evaluation sessions over 1 month from enrollment
|
Game difficulty level when performing a simulated game task using the experimental system.
Levels are 1 (easiest) to 16 (hardest)
|
At each of 4 evaluation sessions over 1 month from enrollment
|
|
Heart rate
Zeitfenster: Before and after each of 4 evaluation sessions over 1 month from enrollment
|
Heart rate (Pulse) measured with a medical meter at start and end of each usability evaluation session
|
Before and after each of 4 evaluation sessions over 1 month from enrollment
|
|
Blood pressure (systolic and diastolic)
Zeitfenster: Before and after each of 4 evaluation sessions over 1 month from enrollment
|
Blood pressure (Systolic and diastolic) measured with a medical meter before and after each Usability evaluation session.
|
Before and after each of 4 evaluation sessions over 1 month from enrollment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Grigore C Burdea, PhD, Bright Cloud Int'l Corp
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Telerehab CH Usability
- R43CA232936 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Usability study
-
Empatica, Inc.United States Department of DefenseAbgeschlossen
-
Istituto Auxologico ItalianoAbgeschlossen
-
University Hospital, AngersZurückgezogenBefriedigung | Hohes Alter | BenutzerfreundlichkeitFrankreich
-
University Hospital, AngersUnbekannt
-
Klein Buendel, Inc.National Institute on Aging (NIA)AbgeschlossenPhysische Aktivität | AlternVereinigte Staaten
-
University Hospital, AngersUnbekanntNeurokognitive Störungen | PatientenzufriedenheitFrankreich
-
Chang Gung Memorial HospitalAbgeschlossen
-
Bright Cloud International CorpNational Institute on Aging (NIA)AbgeschlossenGesundVereinigte Staaten
-
Royal Marsden NHS Foundation TrustFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Cancer Research UK; University... und andere MitarbeiterRekrutierungSarkom | Weichgewebe-Sarkom Erwachsener | Liposarkom | Angiosarkom | Weichteilsarkom des Gliedes | Retroperitoneales Sarkom | Liposarkom, entdifferenziert | Leiomyosarkom (LMS) | Weichteilsarkom des Rumpfes und der Extremitäten | Weichteilsarkom (STS) | Sarkom, Leiomyo-, Erwachsene | Sarkom, Synovial, ErwachseneVereinigtes Königreich
-
Radicle ScienceAbgeschlossenKognitive FunktionVereinigte Staaten